Visual Abstract
Background: Both primary care physicians (PCPs) and endocrinologists (Endos) commonly prescribe T2D medications. This study presents real-world effectiveness of sema OW by prescriber specialty in a cohort of US commercially insured/Medicare Advantage T2D patients newly initiating a GLP-1 agonist.
Methods: Claims and lab result data were used to identify T2D patients who initiated sema OW between 12/1/17 - 6/30/20 (index as first claim). Selected patients had ≥1 A1c result within ≤3 months pre and ≥3 months post-index. Patients with no claim for any GLP-1 agonist in the 12 months pre-index and persistent on sema OW (those with a sema OW prescription with days supply dispensed overlapping/in proximity of date of post-index A1c) were assessed for A1c changes stratified by prescriber specialty (PCPs/Endos) and by pre-index A1c >9%.
Results: A1c was significantly reduced vs. pre-index in 1,284 patients prescribed sema OW by a PCP or Endo (both -1.3%; p<0.001, Figure 1). Significant reductions were also observed by prescriber specialty for patients with a baseline A1c > 9% (both -2.8%; p<0.001). Attainment of A1c <7% and <8% was similar between specialties, with over ½ and ¾ of patients reaching those targets, respectively.
Conclusion: Similar pre/post reductions in A1c were observed when initiating sema OW in T2D GLP-1 agonist naïve patients being treated by PCPs and Endos.
N. Shivappa: Other Relationship; Self; Novo Nordisk. J. Noone: Employee; Self; Novo Nordisk Inc. C. Swift: Employee; Self; Novo Nordisk Inc. S. Du: None. H. Tan: Other Relationship; Self; HealthCore. Y. M. Paprocki: Employee; Self; Novo Nordisk, Stock/Shareholder; Self; Novo Nordisk. V. Willey: Employee; Self; HealthCore.
